And yet there is a good reason why the pharmaceutical industry can and should play a major role in financing something like a common “Innovation Fund” to provide financing for early-stage research into solving the problem of antimicrobial resistance. And that reason is one that I became familiar with during my years at Goldman Sachs: enlightened self-interest.
有一个重要理由认为制药业能够也应该在融资中扮演类似于共同“创新基金”的角色，为解决抗耐药性的早期研究提供资金。而这个理由是我在高盛公司任职期间耳熟能详的：开明自利（enlightened self-interest）